288
Views
303
CrossRef citations to date
0
Altmetric
Mammalian Genetic Models with Minimal or Complex Phenotypes

Evolutionary Divergence of Platelet-Derived Growth Factor Alpha Receptor Signaling Mechanisms

, , &
Pages 4013-4025 | Received 18 Nov 2002, Accepted 17 Mar 2003, Published online: 27 Mar 2023
 

Abstract

Receptor tyrosine kinases (RTKs) direct diverse cellular and developmental responses by stimulating a relatively small number of overlapping signaling pathways. Specificity may be determined by RTK expression patterns or by differential activation of individual signaling pathways. To address this issue we generated knock-in mice in which the extracellular domain of the mouse platelet-derived growth factor alpha receptor (PDGFαR) is fused to the cytosolic domain of Drosophila Torso (αTor) or the mouse fibroblast growth factor receptor 1 (αFR). αTor homozygous embryos exhibit significant rescue of neural crest and angiogenesis defects normally found in PDGFαR-null embryos yet fail to rescue skeletal or extraembryonic defects. This phenotype was associated with the ability of αTor to stimulate the mitogen-activated protein (MAP) kinase pathway to near wild-type levels but failure to completely activate other pathways, such as phosphatidylinositol (PI) 3-kinase. The αFR chimeric receptor fails to rescue any aspect of the PDGFαR-null phenotype. Instead, αFR expression leads to a gain-of-function phenotype highlighted by ectopic bone development. The αFR phenotype was associated with a failure to limit MAP kinase signaling and to engage significant PI3-kinase response. These results suggest that precise regulation of divergent downstream signaling pathways is critical for specification of RTK function.

ACKNOWLEDGMENTS

We thank Jason Frazier and Peter Mueting-Nelsen for excellent technical assistance; Alice Davy, Josée Aubin, and Weisheng Chen for continuing interest and many helpful discussions; Brad Olwin for providing the FGFR1 cDNA; Deborah Morrison for providing the Torso cDNA; I. Lax and J. Schlessinger for the anti-FRS2 antibody; and our laboratory colleagues for critical review of the manuscript.

During the course of this study T.G.H. was supported by National Institutes of Health (NIH) postdoctoral fellowship HD08741-01. This work was supported by NIH grants HD25326 and HD24875 to P.S.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.